[Prediction of relapse-free period after radio- and chemotherapy in patients with breast cancer].
The study was carried out in 55 females with breast cancer stage III-IV, aged 35-77 yrs. The patients received radiation and standard courses of CMF, or CAF, or CMF+trastuzumab, or carboplatin+vepesid, or taxotere+epirubicin, or mustoforan. Radiation was administered in fractionated single focal doses of 3 Gy. S-index was determined before treatment started by an original short (ca. 4 hrs) method of evaluating apoptotic leukocyte DNA disintegration after ex vivo test irradiation as described by Ivanov S.D. et al., 2003. The index ranged 0.40-1.44 rel. units thus correlating with 2-100 month relapse-free period. Direct correlations were identified between S-index and relapse-free period for different regimens of radiochemotherapy. S-index level in excess of 0.95 involved relatively longer relapse-free survival. In summary, our method offers means of predicting the effectiveness of a particular regimen prior to treatment thus making individualization possible.
Ivanov
S D
SD
Iamshanov
V A
VA
Korytova
L I
LI
Khazova
T V
TV
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D018714:Radiotherapy, Adjuvant